An observational study in Stroke and Hyperventilation Syndrome, sponsored by Istinye University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Istinye University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Stroke by Istinye University — 5 open to participants now, 5 under way, none of them phase 3. Stroke · Istinye University.
Among the 13 studies in Stroke by Istinye University, this one is one of 4 that started in 2026, is one of 4 observational ones, and was the 13th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →5 of the 13 studies in Stroke by Istinye University are open now, in 1 country. Recruiting first, the newest first:
Istinye University · Sites in Turkey
Ages 40–70
Istinye University · Sites in Turkey
Ages 18+
Istinye University · Sites in Turkey
Ages 18–75
Istinye University
Ages 40–75
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 92 is below the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 42 across the 9 interventional studies, 60 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istinye University is the lead sponsor of 224 studies on the registry; 96 are open to participants now.
2 of the studies in Stroke by Istinye University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07840703Istinye UniversitySymptomatic Hyperventilation in Individuals Living With Stroke | 2026-12-15 |
| NCT07669246Istinye UniversityInteroception in Stroke | 2026-12-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Stroke by Istinye University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate the effects of hyperventilation syndrome on respiratory muscle strength, respiratory muscle endurance, pulmonary functions, and functional capacity in individuals living with stroke, and in this context, stroke patients with and without hyperventilation syndrome based on Nijmegen Questionnaire scores will be compared to evaluate the relationship between symptom burden and respiratory parameters.
The study population will comprise adult individuals diagnosed with stroke (ischaemic or haemorrhagic) who are in the post-stroke period. Participants will be recruited and screened based on the Nijmegen Questionnaire score to form two distinct cohorts: individuals presenting with symptomatic hyperventilation syndrome and individuals without hyperventilation syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments
Other: Respiratory Function, Respiratory Muscle Strength, and Functional Capacity Assessments
Both groups will undergo comprehensive evaluations including pulmonary function tests (FEV1, FVC, PEF), respiratory muscle strength (PImax, PEmax), respiratory muscle endurance tests, the Nijmegen Questionnaire, and the six-minute walk test (6MWT) to assess functional capacity.
Change in Forced Expiratory Volume in One Second (FEV1 % predicted)
FEV1 percent predicted values will be measured to evaluate and compare pulmonary function between the hyperventilation syndrome group and the control group.
Time frame: Measured at baseline/assessment
Maximal inspiratory pressure (PImax)
Maximal inspiratory pressure will be assessed to determine respiratory muscle strength.
Time frame: Measured at baseline/assessment.
Maximal expiratory pressure (PEmax)
Maximal expiratory pressure will be assessed to determine respiratory muscle strength.
Time frame: Measured at baseline/assessment.
Respiratory Muscle Endurance Score
Respiratory muscle endurance scores will be recorded to evaluate breathing endurance between groups.
Time frame: Measured at baseline/assessment.
Forced Vital Capacity (FVC)
FVC percentage value will be analyzed to assess restrictive patterns and flow rates.
Time frame: Measured at baseline/assessment.
Peak Expiratory Flow (PEF)
PEF value will be analyzed to assess restrictive patterns and flow rates.
Time frame: Measured at baseline/assessment.
Six-Minute Walk Distance (6MWD)
The six-minute walk test will be performed to measure functional capacity distance in meters.
Time frame: Measured at baseline/assessment.
No study locations are listed for this record.
Start is estimated for Sep 2026; primary completion for Dec 2026, 2 months later.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 2 months is below that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.